TYAN
22.6.2020 17:02:12 CEST | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, is showcasing its latest lineup of HPC, storage, cloud and embedded platforms powered by 2nd Gen AMD EPYC™ 7002 series processors and 2nd Gen Intel® Xeon® Scalable Processors at TYAN server solutions online exhibition .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200622005042/en/
“With over 30 years of experience offering state-of-the-art server platforms and server motherboards, TYAN has been recognized by large scale data center customers and server channels,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “Combining the latest innovation from our partners, like Intel and AMD, TYAN customers enable to win the market opportunities precisely with TYAN’s server building block offerings.”
Attendees will experience featured products showcase, webinar sessions and live Q & A during the virtual environment. Heading TYAN’s latest server offerings for the HPC community are Thunder HX FT83-B7119 and Transport HX TS75-B8252 . The FT83-B7119 is built around 2nd Gen Intel Xeon Scalable processors featuring ten double-width PCIe x16 slots for GPUs and 12 hot-swap, tool-less 3.5” drive bays which support up to 4 NVMe U.2 drives in a 4U enclosure. The system is ideal for AI training and inference applications. Powered by 2nd Gen AMD EPYC 7002 series processors, the TS75-B8252 is optimized for virtualization, AI inference and in-memory computing workloads. The 2U server platform features 32 DIMM slots, up to 9 PCIe 4.0 slots, 12 hot-swap, tool-less 3.5” drive bays which support up to 4 NVMe U.2 drives.
Optimized for the challenges facing in Cloud Server Providers, TYAN’s cloud platforms offer outstanding computing density and storage performance in a cost-efficient way. The new 1U Thunder SX GT93-B7106 supports dual socket 2nd Gen Intel Xeon Scalable processors with twelve 3.5” and one 2.5” easy-swap drive bays for software-defined cold storage applications. Featuring 2nd Gen AMD EPYC 7002 series processors, the Transport CX GC68-B8036 accommodates four 3.5” and four 2.5” hot-swap, tool-less drive bays in 1U for both data storage and application cache requirement in data center deployment; the Transport CX TN73-B8037-X4S is a 2U 4-node high-density server platform with support for 16 hot-swap, tool-less 2.5” drive bays supporting both NVMe U.2 and SATA devices. The system is ideal for high IOPs server use cases in data centers.
TYAN offers a full line of storage servers capable of storing massive amounts of data, ranging from 1U high-performance storage server with 12 all-flash drive bays, 2U hybrid storage server to enormous 4U high capacity 100-drive high capacity one. TYAN storage server product line provides a variety of selection for tiered storage requirements in enterprises and data centers.
Please click here for more information and to register.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200622005042/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom